According to Rigel Pharmaceuticals's latest financial reports the company's current revenue (TTM) is $0.11 B. In 2022 the company made a revenue of $0.12 B a decrease over the years 2021 revenue that were of $0.14 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.11 B | -2.79% |
2022 | $0.12 B | -19.43% |
2021 | $0.14 B | 37.39% |
2020 | $0.10 B | 83.21% |
2019 | $59.28 M | 33.2% |
2018 | $44.5 M | 892.62% |
2017 | $4.48 M | -78% |
2016 | $20.38 M | -29.46% |
2015 | $28.89 M | 250.24% |
2014 | $8.25 M | 15.38% |
2013 | $7.15 M | 217.78% |
2012 | $2.25 M | -52.63% |
2011 | $4.75 M | -96.2% |
2010 | $0.12 B | 16566.67% |
2009 | $0.75 M | |
2006 | $33.47 M | 102.55% |
2005 | $16.52 M | 249.17% |
2004 | $4.73 M | -57.19% |
2003 | $11.05 M | -29.98% |
2002 | $15.78 M | 3.18% |
2001 | $15.3 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Amgen AMGN | $28.19 B | 24,018.34% | ๐บ๐ธ USA |
AstraZeneca AZN | $47.61 B | 40,634.24% | ๐ฌ๐ง UK |
Sangamo Therapeutics
SGMO | $0.17 B | 50.78% | ๐บ๐ธ USA |
ChemoCentryx CCXI | $37.2 M | -68.17% | ๐บ๐ธ USA |